Video
24 Sep 2021
We Are DFE Pharma
![](/DFE_LOGO_CMYK-file121383.jpg)
Content provided by our supplier
DFE Pharma
![DFE Pharma](/DFE_LOGO_RGB-comp245460.jpg)
-
DE
-
2015On CPHI since
-
1Certificates
-
250 - 499Employees
Company types
Other Content from DFE Pharma (5)
-
News Excipients – an industry adapting to change
Excipients are a crucial component of the pharmaceutical product formulation, and the industry is constantly having to adapt to changes in demand and technology innovations -
Whitepaper Nitrosamines Risk Mitigation
Assessing nitrosamines in drug products has become one of the top challenges for formulators in the pharmaceutical industry.
During drug product risk evaluation, excipients play a crucial role. Although the risk of nitrosamine presence is low, some excipients contain trace amounts of nitrites. Under specific conditions, these traces can lead to nitrosamine formation within the drug product.
Different studies reveal varying nitrite levels among different excipients and even within the same type from different suppliers. Comparing excipient types and suppliers is essential for risk mitigation during production.
-
Video Closer to the Formulator (C2F) Center
The new Center of Excellence “Closer to the Formulator” (C2F) by DFE Pharma helps pharmaceutical companies to shorten the time from a concept to a finished commercial product through expertise in all phases of pharmaceutical development.
The services offered by this new state-of-the-art facility, are mainly focused on Oral Solid Dosage (OSD) forms, comprising all types of pre-registration work including development, intermediate scale-up, and technology transfer.
The C2F offerings can provide pharmaceutical companies with multiple advantages as, for example, it aims to significantly lower the number of development cycles and aspires to reduce formulation costs, when launching a medicine.
-
Whitepaper Understanding and Accounting for Excipient Variability in Continuous Tablet Manufacturing (CM)
As pharmaceutical production moves from batch-wise to continuous manufacturing, individual processing steps, such as blending of the active pharmaceutical ingredient (API) with excipients, have to be re-designed to continuous operations.
Whilst the cost and quality benefits of CM are well documented, successful implementation relies on an in-depth understanding of how raw materials and their mixtures – including excipients – behave in continuous processes. This whitepaper will outline some of the key learnings from DFE Pharma’s excipients in CM processes variability experiments, before setting out DFE Pharma’s Stretch Batch Approach and how it can work in practice.
Ultimately, it will demonstrate why DFE Pharma is fast becoming the pharma industry’s preferred global partner in the robust development of continuous tablet manufacturing processes. -
Video DFE Pharma Norten Hardenberg, Germany
DFE Pharma's Norten Hardenberg plant, located in Germany, is dedicated to the production of anhydrous lactose. An investment for the future, featuring a new state-of-the-art production line, like for like process, high-end control to ensure batch homogeneity.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance